India, Jan. 18 -- Johnson & Johnson announced that Janssen Pharmaceuticals, Inc., member of the Johnson & Johnson Family of Companies, entered into a research study in collaboration with Apple Inc. to investigate whether a new heart health program using an app from Johnson & Johnson in combination with Apple Watch's irregular rhythm notifications and ECG app can accelerate the diagnosis and improve health outcomes of the 33 million people worldwide living with atrial fibrillation (AFib),a condition that can lead to stroke and other potentiallydevastating complications. In the U.S. alone, AFibis responsible for approximately 130,000 deaths and 750,000 hospitalizations every year.

The study aims to analyze the impact of Apple Watch on the ...